UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549




                                    FORM 8-K
                                 CURRENT REPORT
          Pursuant to Section 13 or 15(d) of the Securities Act of 1934

                Date of Report (Date of earliest event reported)
                                December 2, 2004


                              OCEAN BIO-CHEM, INC.



      Florida                 2-70197                               59-1564329
      --------               --------                            --------------
(State or other          (Commission File Number)                (IRS Employer
jurisdiction of                                                  Identification
 Incorporation)                                                      Number)



                               4041 S.W. 47 Avenue
                          Fort Lauderdale, Florida 3314
               (Address of Principal Executive Offices) (Zip Code)


                                 (954) 587-6280
              (Registrant's telephone number, including area code)

            (Former name of Registrant, if changed since last report)
                                       N/A

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions:

(  )  Written communication pursuant to Rule 425 under the Securities Act
        (17 CFR 230.425)

(  )  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
        (17 CFR 240.14a-12)

(  )  Pre-commencement communication pursuant to Rule 14d-2(b) under the
        Exchange Act (17 CFR 240.14d-2(b))

(  )  Pre-commencement communication pursuant to Rule 13e-4(c) under the
        Exchange Act (17 CFR 240.13e-4(c))




Item 8.01    Other Events

     On December 2, 2004 the Company  issued a press release  reporting that the
Board of Directors of the Company had authorized a Stock Repurchase Program. The
terms  of the  program,  intended  to  comply  with  Rule  10b-18,  contemplates
repurchases of Company stock when available at or below the Company's book value
and with a maximum  expenditure  of  $50,000  by the  Company.  The  program  is
authorized for six months unless extended by the Board of Directors.



                                   SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.


                                         Ocean Bio-Chem, Inc.


                                         /s/ Peter G. Dornau
                                         -------------------------------------
                                         Peter G. Dornau
                                         Chairman of the Board and
                                         Chief Executive Officer